Twist Bioscience (TWST) Total Non-Current Liabilities (2018 - 2026)

Twist Bioscience (TWST) has reported Total Non-Current Liabilities for 9 consecutive years, with $220.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 33.69% year-over-year to $220.2 million in Q2 2026; TTM through Jun 2026 was $220.2 million, a 33.69% increase from a year earlier, with the FY2025 full-year figure at $168.2 million, up 19.07% from the prior year.
• Total Non-Current Liabilities was $220.2 million for Q2 2026 at Twist Bioscience, roughly flat from $220.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $220.4 million in Q1 2026 and troughed at $141.2 million in Q3 2024.
• A 5-year average of $162.9 million and a median of $153.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 139.49% in 2022 and declined 13.01% in 2023, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $163.6 million in 2022, then slipped by 13.01% to $142.3 million in 2023, then advanced by 6.98% to $152.2 million in 2024, then grew by 19.06% to $181.2 million in 2025, then gained by 21.5% to $220.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $220.2 million (Q2 2026), $220.4 million (Q1 2026), and $181.2 million (Q4 2025), per Business Quant data.